Join
Live feed
·
PRReleasevia Quantisnow
Aclaris Therapeutics Inc. logo

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

ByQuantisnow·Wall Street's wire, on your screen.
ACRS· Aclaris Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRS (Aclaris Therapeutics Inc.) and more on Quantisnow.